
    
      The objective of this study is to evaluate the effects of intravenous ANX005 administered for
      up to 22 weeks in subjects with, or at risk for, manifest Huntington's Disease.

      Subjects will receive induction dosing of ANX005 administered by IV infusion on Days 1 and 5
      or 6, followed by maintenance dosing every 2 weeks through Week 22, with follow up visits on
      Weeks 24, 28, and 36.

      All subjects will be contacted (in clinic visit or phone call) 6 months after study
      completion.
    
  